Winston Obtains Patent Win for Watson

On July 27, 2018, Winston & Strawn obtained a favorable result for our client Watson Pharmaceuticals (a subsidiary of Teva Pharmaceuticals) when the court found that Watson does not infringe the claims of Amgen’s sole unexpired patent for Senispar®, which generates over $1.3 billion in annual sales. 

Federal District Judge Mitchell S. Goldberg, sitting in the District of Delaware, issued the decision after a four-day bench trial in March involving Amgen, Watson, and four other generic pharmaceutical manufacturers. At trial, the Winston team took the lead with respect to common issues for all five separately represented generic manufacturers in the joint defense group, delivering the opening statement and portions of the closing argument on their behalf. In his opinion, Judge Goldberg agreed with Winston’s arguments that Watson did not infringe Amgen’s patent under the doctrine of equivalents.

The case was tried by Winston Chicago-based Partners George Lombardi and Chris Essig, and the team included Associates Zack Sorman, Alison Cooney, Pat O’Meara, Liz Grden, and Schuyler Ferguson.